Prefilled syringes continue to gain popularity for drug delivery with more U.S. biopharmaceutical companies moving away from vials in advance of the upcoming flu season, reports In-PharmaTechnologist. Prefilled syringes are secure, easy to use, minimize the chance for dosage error and increase patient compliance.
In-PharmaTechnologist reports that even though Europe has adopted prefilled syringes in greater numbers, the shift has picked up in the past few months. "There's been a migration to more prefill applications for the upcoming flu season [in the US]," Bill Kozy, executive vice president at medical supply company BD, said in a conference call, adding that the company has done its part to make the shift happen with its "vial to prefill strategy," In-PharmaTechnologist reports.
BD's clients in the United States have added $9 million to third-quarter sales, according to the report, with U.S. sales getting a boost from "a big pharmaceutical client shifting its sourcing from Europe to North America."
- read more in In-PharmaTechnologist